|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets: | ||||||||||||||
| Cash and cash equivalents | ||||||||||||||
| Accounts receivable, net of allowance for credit losses of $15 and $182 as of June 30, 2024 and December 31, 2023, respectively | ||||||||||||||
| Contract assets, net | ||||||||||||||
| Inventory | ||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||
| Total current assets | ||||||||||||||
| Investments held in Trust Account | ||||||||||||||
| Property, plant, and equipment, net | ||||||||||||||
| Other assets | ||||||||||||||
| Total assets | ||||||||||||||
| Liabilities and shareholders' deficit: | ||||||||||||||
| Accrued expenses | ||||||||||||||
| Accounts payable and accrued expenses | ||||||||||||||
| Accrued offering costs | ||||||||||||||
| Advances from related party | ||||||||||||||
| Current portion of long-term debt | ||||||||||||||
| Accounts payable | ||||||||||||||
| Contract liabilities | ||||||||||||||
| Reserve for anticipated losses on contracts | ||||||||||||||
| Accrued expenses and other current liabilities | ||||||||||||||
| Total current liabilities | ||||||||||||||
| Deferred underwriting fee payable | ||||||||||||||
| Long-term debt | ||||||||||||||
| Warrant liabilities | ||||||||||||||
| Warrant and derivative liabilities | ||||||||||||||
| Other liabilities | ||||||||||||||
| Total liabilities | ||||||||||||||
| Redeemable convertible preferred stock - authorized zero and 20,526,878 shares of $0.0001 par value as of December 31, 2022 and 2021, respectively; issued and outstanding shares of zero and 10,947,686 as of December 31, 2022 and 2021, respectively | ||||||||||||||
| Class A Ordinary shares subject to possible redemption | ||||||||||||||
| Redeemable Convertible Preferred Stock | ||||||||||||||
| Total redeemable convertible preferred stock - authorized zero and 20,526,878 shares of $0.0001 par value as of December 31, 2022 and 2021, respectively; issued and outstanding shares of zero and 10,947,686 as of December 31, 2022 and 2021, respectively | ||||||||||||||
| Shareholders' deficit: | ||||||||||||||
| Preferred stock - authorized 50,000,000 shares of $0.0001 par value; zero issued and outstanding as of June 30, 2024 and December 31, 2023 | ||||||||||||||
| Common stock - authorized 600,000,000 shares of $0.0001 par value; issued and outstanding shares of 203,527,577 and 199,413,917 as of June 30, 2024 and December 31, 2023, respectively | ||||||||||||||
| Class B Ordinary shares | ||||||||||||||
| Total common stock - authorized 600,000,000 shares of $0.0001 par value; issued and outstanding shares of 203,527,577 and 199,413,917 as of June 30, 2024 and December 31, 2023, respectively | ||||||||||||||
| Additional paid-in capital | ||||||||||||||
| Accumulated deficit | ||||||||||||||
| Total Shareholders' (Deficit) Equity | ||||||||||||||
| Accumulated other comprehensive income | ||||||||||||||
| Total shareholders' deficit | ||||||||||||||
| Total liabilities and shareholders' deficit | ||||||||||||||
Loading...
